Radiolabeled ether dendrimer conjugates for pet imaging and radiotherapy
AssigneeAshvattha Therapeutics, Inc.
InventorsJeffrey L. Cleland, Rishi Sharma, Minghao Sun, Santiago Appiani La Rosa
Life of this patent
Estimating the term…
Loading patent…
AssigneeAshvattha Therapeutics, Inc.
InventorsJeffrey L. Cleland, Rishi Sharma, Minghao Sun, Santiago Appiani La Rosa
Estimating the term…
Compositions and methods for detecting, monitoring and imaging inflammatory sites or tumors in a subject have been developed. Compositions of hydroxyl-terminated dendrimers conjugated to radionuclide(s) via ether linkages are provided for both imaging and radiotherapy (tumors). Methods for the non-invasive and specific positron emission tomography (PET) imaging or magnetic resonance imaging (MRI) of dendrimer conjugated to one or more imaging agents in a subject in vivo are also provided. The methods selectively deliver dendrimer conjugated to radionuclides or MRI contrast agents to reactive microglia or reactive immune cells in tumors in the recipient. In some embodiments, the dendrimers conjugated to imaging agents also deliver targeted radiotherapy agents to a tumor, and/or deliver additional diagnostic, therapeutic or prophylactic agents to reactive microglia in the recipient. Methods of making dendrimers conjugated to imaging agents are also described.
A composition comprising hydroxyl-terminated dendrimers conjugated to one or more radionuclides or one or more magnetic resonance imaging (MRI) contrast agents through ether linkages, optionally via one or more linking moieties.
A composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.
A method for detecting or imaging one or more inflammatory and/or cancer cells in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.
A method for treating cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.
A method of making hydroxyl dendrimers covalently conjugated via ether linkages to one or more positron emission tomography (PET) imaging agents or one or more magnetic resonance imaging (MRI) contrast agents, the method comprising etherification of one or more surface groups of the dendrimers prior to conjugation the one or more surface groups of the dendrimers to one or more PET imaging agents, optionally via one or more spacers, and wherein the conjugation is via an ether linkage.
A method for treating a neurodegenerative disorder comprising administering to a subject in need thereof an effective amount of a composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.
Dependencies are inferred from the claim text.